Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study

Cristina Maccalli, Diana Giannarelli, Filippo Capocefalo, Lorenzo Pilla, Ester Fonsatti, Anna Maria Di Giacomo, Giorgio Parmiani, Michele Maio

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Clinical activity was observed in metastatic melanoma (MM) patients treated with ipilimumab (IPI) combined with fotemustine (FTM) in the phase II NIBIT-M1 study. Peripheral blood mononuclear cells (PBMCs) and serum were collected from MM patients at pre- and at weeks 12 and 24 post-treatment. A comprehensive phenotypic and functional immunomonitoring of circulating T cells, and the detection of soluble immunoregulatory molecules was carried out and correlated with clinical outcome. The frequency at baseline and along the treatment of circulating T central memory cells expressing activation/differentiation markers, such as CD3+CD4+CD45RO+BTLA+, CD3+CD4+4–1BB or Th17 lymphocytes correlated with the clinical outcome of MM patients. Moreover, either the absence or the presence of soluble NKG2D ligands (ULBP-1 or −2) at baseline in the serum of MM patients enabled to discriminate subjects with long-term survival (median overall survival, (OS) = 33.6 mo for ULBP-1 and −2) from poor survivors (OS = 9.8 or 6.6 mo, respectively). Conversely, no significant association between the levels of soluble MICA, MICB and ULBP-3 and the clinical outcome of patients was observed. An inverse correlation between circulating levels of these molecules at baseline and frequency of either CD3+CD4+CD45RO+BTLA+ or Th17 or CD3+CD4+4–1BB+ T cells occurred in patients with a favorable clinical outcome. The simultaneous monitoring of different immune parameters, though validation in a large cohort of patients is needed, allowed to identify an association between phenotypic and soluble markers representing a possible predictive immunological signature for the clinical activity of IPI plus FTM.

Original languageEnglish
JournalOncoImmunology
Volume5
Issue number2
DOIs
Publication statusPublished - 1 Feb 2016
Externally publishedYes

Fingerprint

fotemustine
Melanoma
Biomarkers
Survival
T-Lymphocytes
Immunologic Monitoring
Differentiation Antigens
ipilimumab
Serum
Survivors
Blood Cells

Keywords

  • Cytotoxic T-lymphocyte Antigen-4 (CTLA-4)
  • Melanoma
  • NKG2D ligands
  • T cell subsets

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study. / Maccalli, Cristina; Giannarelli, Diana; Capocefalo, Filippo; Pilla, Lorenzo; Fonsatti, Ester; Di Giacomo, Anna Maria; Parmiani, Giorgio; Maio, Michele.

In: OncoImmunology, Vol. 5, No. 2, 01.02.2016.

Research output: Contribution to journalArticle

Maccalli, Cristina ; Giannarelli, Diana ; Capocefalo, Filippo ; Pilla, Lorenzo ; Fonsatti, Ester ; Di Giacomo, Anna Maria ; Parmiani, Giorgio ; Maio, Michele. / Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study. In: OncoImmunology. 2016 ; Vol. 5, No. 2.
@article{42e8e21cb8304bc8ad9ce07c97982ecc,
title = "Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study",
abstract = "Clinical activity was observed in metastatic melanoma (MM) patients treated with ipilimumab (IPI) combined with fotemustine (FTM) in the phase II NIBIT-M1 study. Peripheral blood mononuclear cells (PBMCs) and serum were collected from MM patients at pre- and at weeks 12 and 24 post-treatment. A comprehensive phenotypic and functional immunomonitoring of circulating T cells, and the detection of soluble immunoregulatory molecules was carried out and correlated with clinical outcome. The frequency at baseline and along the treatment of circulating T central memory cells expressing activation/differentiation markers, such as CD3+CD4+CD45RO+BTLA+, CD3+CD4+4–1BB or Th17 lymphocytes correlated with the clinical outcome of MM patients. Moreover, either the absence or the presence of soluble NKG2D ligands (ULBP-1 or −2) at baseline in the serum of MM patients enabled to discriminate subjects with long-term survival (median overall survival, (OS) = 33.6 mo for ULBP-1 and −2) from poor survivors (OS = 9.8 or 6.6 mo, respectively). Conversely, no significant association between the levels of soluble MICA, MICB and ULBP-3 and the clinical outcome of patients was observed. An inverse correlation between circulating levels of these molecules at baseline and frequency of either CD3+CD4+CD45RO+BTLA+ or Th17 or CD3+CD4+4–1BB+ T cells occurred in patients with a favorable clinical outcome. The simultaneous monitoring of different immune parameters, though validation in a large cohort of patients is needed, allowed to identify an association between phenotypic and soluble markers representing a possible predictive immunological signature for the clinical activity of IPI plus FTM.",
keywords = "Cytotoxic T-lymphocyte Antigen-4 (CTLA-4), Melanoma, NKG2D ligands, T cell subsets",
author = "Cristina Maccalli and Diana Giannarelli and Filippo Capocefalo and Lorenzo Pilla and Ester Fonsatti and {Di Giacomo}, {Anna Maria} and Giorgio Parmiani and Michele Maio",
year = "2016",
month = "2",
day = "1",
doi = "10.1080/2162402X.2015.1071007",
language = "English",
volume = "5",
journal = "OncoImmunology",
issn = "2162-4011",
publisher = "Landes Bioscience",
number = "2",

}

TY - JOUR

T1 - Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study

AU - Maccalli, Cristina

AU - Giannarelli, Diana

AU - Capocefalo, Filippo

AU - Pilla, Lorenzo

AU - Fonsatti, Ester

AU - Di Giacomo, Anna Maria

AU - Parmiani, Giorgio

AU - Maio, Michele

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Clinical activity was observed in metastatic melanoma (MM) patients treated with ipilimumab (IPI) combined with fotemustine (FTM) in the phase II NIBIT-M1 study. Peripheral blood mononuclear cells (PBMCs) and serum were collected from MM patients at pre- and at weeks 12 and 24 post-treatment. A comprehensive phenotypic and functional immunomonitoring of circulating T cells, and the detection of soluble immunoregulatory molecules was carried out and correlated with clinical outcome. The frequency at baseline and along the treatment of circulating T central memory cells expressing activation/differentiation markers, such as CD3+CD4+CD45RO+BTLA+, CD3+CD4+4–1BB or Th17 lymphocytes correlated with the clinical outcome of MM patients. Moreover, either the absence or the presence of soluble NKG2D ligands (ULBP-1 or −2) at baseline in the serum of MM patients enabled to discriminate subjects with long-term survival (median overall survival, (OS) = 33.6 mo for ULBP-1 and −2) from poor survivors (OS = 9.8 or 6.6 mo, respectively). Conversely, no significant association between the levels of soluble MICA, MICB and ULBP-3 and the clinical outcome of patients was observed. An inverse correlation between circulating levels of these molecules at baseline and frequency of either CD3+CD4+CD45RO+BTLA+ or Th17 or CD3+CD4+4–1BB+ T cells occurred in patients with a favorable clinical outcome. The simultaneous monitoring of different immune parameters, though validation in a large cohort of patients is needed, allowed to identify an association between phenotypic and soluble markers representing a possible predictive immunological signature for the clinical activity of IPI plus FTM.

AB - Clinical activity was observed in metastatic melanoma (MM) patients treated with ipilimumab (IPI) combined with fotemustine (FTM) in the phase II NIBIT-M1 study. Peripheral blood mononuclear cells (PBMCs) and serum were collected from MM patients at pre- and at weeks 12 and 24 post-treatment. A comprehensive phenotypic and functional immunomonitoring of circulating T cells, and the detection of soluble immunoregulatory molecules was carried out and correlated with clinical outcome. The frequency at baseline and along the treatment of circulating T central memory cells expressing activation/differentiation markers, such as CD3+CD4+CD45RO+BTLA+, CD3+CD4+4–1BB or Th17 lymphocytes correlated with the clinical outcome of MM patients. Moreover, either the absence or the presence of soluble NKG2D ligands (ULBP-1 or −2) at baseline in the serum of MM patients enabled to discriminate subjects with long-term survival (median overall survival, (OS) = 33.6 mo for ULBP-1 and −2) from poor survivors (OS = 9.8 or 6.6 mo, respectively). Conversely, no significant association between the levels of soluble MICA, MICB and ULBP-3 and the clinical outcome of patients was observed. An inverse correlation between circulating levels of these molecules at baseline and frequency of either CD3+CD4+CD45RO+BTLA+ or Th17 or CD3+CD4+4–1BB+ T cells occurred in patients with a favorable clinical outcome. The simultaneous monitoring of different immune parameters, though validation in a large cohort of patients is needed, allowed to identify an association between phenotypic and soluble markers representing a possible predictive immunological signature for the clinical activity of IPI plus FTM.

KW - Cytotoxic T-lymphocyte Antigen-4 (CTLA-4)

KW - Melanoma

KW - NKG2D ligands

KW - T cell subsets

UR - http://www.scopus.com/inward/record.url?scp=84959378635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959378635&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2015.1071007

DO - 10.1080/2162402X.2015.1071007

M3 - Article

VL - 5

JO - OncoImmunology

JF - OncoImmunology

SN - 2162-4011

IS - 2

ER -